BiBBInstruments (BIBB) Q2 2025 earnings summary

Executive summary

• Secured an exclusive US distribution agreement with TaeWoong Medical USA for EndoDrill® GI, with a targeted launch in fall 2025 and broader rollout in 2026.

• Achieved key patent milestones: first US patent for EndoDrill® to be granted, and third Japanese patent approved.

• Transitioned to a new Swedish contract manufacturer, ensuring scalable, high-quality production.

• EndoDrill® GI received positive clinical feedback, with 100% diagnostic accuracy in multiple studies.

Financial highlights

• Q2 2025 net sales were 0 KSEK (0 KSEK in Q2 2024); H1 2025 net sales reached 39 KSEK (0 KSEK in H1 2024).

• Q2 2025 result after financial items was -3,806 KSEK (-3,580 KSEK in Q2 2024); H1 2025 result was -6,693 KSEK (-6,551 KSEK in H1 2024).

• Cash and cash equivalents at June 30, 2025, were 15,814 KSEK (10,476 KSEK a year earlier).

• Equity at period end was 45,550 KSEK (34,537 KSEK in 2024).

• Solid equity ratio of 94.9% (92.8% in 2024).

Outlook and guidance

• Focused on US market entry with EndoDrill® GI and building clinical evidence.

• Broader US launch planned for 2026, with European distribution agreements and EndoDrill® EBUS launch also targeted for 2026.

• Ongoing development and clinical studies for new product variants, including EndoDrill® EBUS and URO.